» Articles » PMID: 37332979

Association of Long Noncoding RNA MALAT1 with the Radiosensitivity of Lung Adenocarcinoma Cells Via the MiR-140/PD-L1 Axis

Overview
Journal Heliyon
Specialty Social Sciences
Date 2023 Jun 19
PMID 37332979
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To investigate the effect of MALAT1 on the modulating the radiosensitivity of lung adenocarcinoma, through regulation of the expression of the miR-140/PD-L1 axis.

Methods: The online databases UALCAN and dbDEMC were searched for the MALAT1 and miR-140 expressions in patients with lung adenocarcinoma (LUAD), respectively. Then analyze their relationship with overall survival rates separately in the UALCAN and ONCOMIR databases. A functional analysis was performed for A549 cells by transfecting small-interfering RNAs or corresponding plasmids after radiotherapy. Xenograft models of LUAD exposed to radiation were established to further observe the effects of MALAT1 on the radiosensitivity of LUAD. The luciferase assay and reverse transcription-polymerase chain reaction were performed to assess the interaction between miR-140 and MALAT1 or PD-L1.

Results: MALAT1 were overexpressed in human LUAD tumor tissues and cell lines, while miR-140 were inhibited. MALAT1 knockdown or miR-140 increase suppressed cell proliferation and promoted cell apoptosis in LUAD after irradiation. LUAD xenograft tumor growth was also inhibited by MALAT1 knockdown combined with irradiation. miR-140 could directly bind with MALAT1 or PD-L1. Furthermore, MALAT1 knockdown inhibited PD-L1 mRNA and protein expressions by upregulating miR-140 in LUAD cells.

Conclusion: MALAT1 may function as a sponge for miR-140a-3p to enhance the PD-L1 expression and decrease the radiosensitivity of LUAD. Our results suggest that MALAT1 might be a promising therapeutic target for the radiotherapy sensitization of LUAD.

Citing Articles

Comprehensive insights and In silico analysis into the emerging role of LincRNAs in lung diseases pathogenesis; a step toward ncRNA precision.

Hamdy N, Zaki M, Abdelmaksoud N, Elshaer S, Abd-Elmawla M, Rizk N Funct Integr Genomics. 2025; 25(1):34.

PMID: 39912974 PMC: 11802690. DOI: 10.1007/s10142-025-01540-1.


Establishment of potential lncRNA-related hub genes involved competitive endogenous RNA in lung adenocarcinoma.

Li Y, Shi D, Jiang Y, Hu Y, Liu Q, Xie Y BMC Cancer. 2024; 24(1):1371.

PMID: 39522011 PMC: 11549862. DOI: 10.1186/s12885-024-13144-2.


MicroRNAs as regulators of immune checkpoints in cancer immunotherapy: targeting PD-1/PD-L1 and CTLA-4 pathways.

Zabeti Touchaei A, Vahidi S Cancer Cell Int. 2024; 24(1):102.

PMID: 38462628 PMC: 10926683. DOI: 10.1186/s12935-024-03293-6.

References
1.
Wei S, Wang K, Huang X, Zhao Z, Zhao Z . LncRNA MALAT1 contributes to non-small cell lung cancer progression via modulating miR-200a-3p/programmed death-ligand 1 axis. Int J Immunopathol Pharmacol. 2019; 33:2058738419859699. PMC: 6595645. DOI: 10.1177/2058738419859699. View

2.
Humphries B, Wang Z, Yang C . MicroRNA Regulation of Breast Cancer Stemness. Int J Mol Sci. 2021; 22(7). PMC: 8038508. DOI: 10.3390/ijms22073756. View

3.
Ji X, Wang E, Tian F . MicroRNA-140 suppresses osteosarcoma tumor growth by enhancing anti-tumor immune response and blocking mTOR signaling. Biochem Biophys Res Commun. 2017; 495(1):1342-1348. DOI: 10.1016/j.bbrc.2017.11.120. View

4.
Melendez-Zajgla J, Maldonado V . The Role of lncRNAs in the Stem Phenotype of Pancreatic Ductal Adenocarcinoma. Int J Mol Sci. 2021; 22(12). PMC: 8232220. DOI: 10.3390/ijms22126374. View

5.
Lin L, Li H, Zhu Y, He S, Ge H . Expression of metastasis-associated lung adenocarcinoma transcript 1 long non-coding RNA and in patients with non-small cell lung cancer. Oncol Lett. 2018; 15(6):9443-9449. PMC: 5958634. DOI: 10.3892/ol.2018.8531. View